Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy

Journal of the National Medical Association

Volumn 99, Issue 7, 2007, Pages 799-801

  Nagajothi, Nagaprasad ^a   Dham, Sandeep K ^b   Gelfand, Yevgeniy ^b   Sanmugarajah, Jasotha ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Downstate Health Sciences University   (United States)

Author keywords

Chemotherapy; HIV AIDS; Lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LAMIVUDINE; LOPINAVIR; PREDNISONE; RITONAVIR; TENOFOVIR; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANAPLASTIC LARGE CELL LYMPHOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; IMAGING; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE-CELL; MALE; MIDDLE AGED; PREDNISONE; VINCRISTINE;

EID: 34447521995     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Agnarsson BA, Kadin M. Ki-1 positive large cell lymphoma: a morphologic and immunologic study of 19 cases. Am J Surg Pathol. 1988;12:264-274.
2. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995;86:1954-1960.
3. Herbst H, Anagnostopoulos J, Heinze B, et al. ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease. Blood. 1995;86:1694-1700.
4. Morton M, Wang S, Devesa S, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
5. Chadburn A, Cesarman E, Jagirdar J, et al. CD30(Ki-1) Positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer. 1993;72:3078-3090.
6. Little R, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653-4659.
7. Bower M, Gazzard B, Mandlia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005;143:265-273.
8. Stein H, Foss HD, Durkop H, et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695.
9. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913-3921.
10. Peng YL, Huang HQ, Lin XB, et al. Clinical outcomes of patients with peripheral T-cell lymphoma treated with EPOCH regimen. Ai Zheng. 2004;23:943-946.